1. Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.
- Author
-
van Trigt, Victoria R., Bakker, Leontine E. H., Lu, Huangling, Pelsma, Iris C. M., Verstegen, Marco J. T., van Furth, Wouter R., Pereira Arias-Bouda, Lenka M., and Biermasz, Nienke R.
- Abstract
Purpose: To assess the utility of [
18 F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([18 F]FET-PET/MRICR ) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning. Methods: Retrospective cohort study of 17 consecutive patients with prolactinoma undergoing [18 F]FET-PET/MRICR between October 2020 and September 2022 for either (1) additional information in case of difficult-to-visualize remnants after prior transsphenoidal surgery (TSS), or pharmacological treatment, or (2) radiological diagnosis in absence of a (clear) adenoma on diagnostic/post-treatment conventional MRI. Results: [18 F]FET-PET/MRICR identified a lesion in 14/17 patients, yet failed to identify active lesions in 2 patients with negative conventional MRI despite prolactin > 7.5 times upper limit of normal. [18 F]FET-PET/MRICR results were inconclusive in 1 patient due to diffuse tracer uptake 10 weeks post-surgery. [18 F]FET-PET/MRICR was completely concordant with a suspected lesion on conventional MRI in 10/17 patients, and partially concordant in 3/17 patients. New foci were identified in 4/17 patients. The [18 F]FET-PET/MRICR conclusions influenced clinical shared decision-making in 15/17 patients, of whom 7 patients underwent TSS and 8 refrained from TSS. One patient underwent TSS despite negative [18 F]FET-PET/MRICR , and one patient underwent additional imaging. Intraoperative findings corresponded with [18 F]FET-PET/MRICR in 5/8 patients, and immunohistochemistry was positive in 5/8 patients. The treatment goal was achieved in 7/8 patients, and remission was achieved in 5/7 patients in whom total resection was considered feasible. Conclusion: [18 F]FET-PET/MRICR can be of added value in the preoperative decision-making process for selected patients with difficult-to-localize prolactinoma (remnants), or patients lacking a substrate on conventional MRI. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF